Pure Global

Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis - Trial NCT06154187

Access comprehensive clinical trial information for NCT06154187 through Pure Global AI's free database. This Phase 3 trial is sponsored by Pharmbio Korea Co., Ltd. and is currently Not yet recruiting. The study focuses on Osteoporosis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06154187
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06154187
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

Study Focus

Osteoporosis

PBK_L2201

Interventional

drug

Sponsor & Location

Pharmbio Korea Co., Ltd.

Seoul, South Korea

Timeline & Enrollment

Phase 3

Feb 01, 2024

Nov 01, 2025

60 participants

Primary Outcome

Bone mineral density (BMD) change rate

Summary

This clinical trial was multicenter, randomized, double-blind, placebo-controlled, parallel,
 phase III bridge study.

ICD-10 Classifications

Osteoporosis, unspecified
Other osteoporosis
Idiopathic osteoporosis
Osteoporosis in diseases classified elsewhere
Postmenopausal osteoporosis

Data Source

ClinicalTrials.gov

NCT06154187

Non-Device Trial